Pfizer终止了与Sangamo的基因治疗合作,导致库存下降60%。 Pfizer ends gene therapy collaboration with Sangamo, causing stock to plummet 60%.

Pfizer终止了与Sangamo治疗师的合作,为A型血友病开发基因疗法,导致Sangamo的股价下跌60%。 Pfizer has ended its collaboration with Sangamo Therapeutics for developing a gene therapy for hemophilia A, leading to a 60% drop in Sangamo's stock price. Sangamo现在将重新获得获得治疗的充分权利,并寻求新的伙伴继续发展。 Sangamo will now regain full rights to the therapy and seek new partners to continue its development. 该协议于2017年签署,计划于2025年初提交监管呈文,但辉瑞公司决定不继续。 The agreement, signed in 2017, had planned for regulatory submissions in early 2025, but Pfizer decided not to proceed.